Back to mobile site
Get it on Google Play

Evaxion reports 3-year melanoma vaccine data ahead of ESMO 2026

October 19, 2026 3:00 AM EDT Send to a Friend
Evaxion A/S (NASDAQ: EVAX) announced three-year follow-up data from its phase 2 trial of personalized cancer vaccine EVX-01 in patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login